Skip to Main Content
Back to News

Lobbying Update: $80,000 of BIO-RAD LABORATORIES lobbying was just disclosed

None

$80,000 of BIO-RAD LABORATORIES lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Issues related to biomedical research and development; Issues related to pathogen surveillance. Issues related to biomedical research and development; Issues related to pathogen surveillance."

You can find more data on corporate lobbying on Quiver Quantitative.

BIO Hedge Fund Activity

We have seen 194 institutional investors add shares of BIO stock to their portfolio, and 210 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

BIO Analyst Ratings

Wall Street analysts have issued reports on $BIO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • RBC Capital issued a "Outperform" rating on 10/31/2024
  • Citigroup issued a "Buy" rating on 10/31/2024

To track analyst ratings and price targets for BIO, check out Quiver Quantitative's $BIO forecast page.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Add Quiver Quantitative to your Google News feed.Google News Logo

Suggested Articles